drugset / Trial / NCT01918761
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
NaSingle-groupOpen-labelTreatment
Summary
To identify a dose of dacomitinib in combination with pemetrexed that is safe and tolerated as determined by the incidence of DLTs (dose limiting toxicities).
Timeline
- Start
- 2013-07-30
- Primary completion
- 2016-09-15
- Completion
- 2016-09-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DACOMITINIB ANHYDROUS | Small molecule | 45 mg | Oral |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |